Sarah is a Managing Partner based in the UK with over 30 years' global experience in strategy and drug development from pre-entry into man to successful NDA approvals.

Sarah is a specialist in strategy and clinical development, having worked extensively in Rare and Neglected Diseases (in particular malaria), Cardiovascular Disease, and Oncology. Having worked across many functional areas and therapeutic areas, Sarah is a well known project leader with a proven track record.

During her career, Sarah has worked in the pharmaceutical industry in Servier, Sanofi, and Grünenthal, before heading up Operations at Fulcrum Pharma Developments.

Sarah has a PhD in Biochemistry from the University of Bath and is an Honorary Member of the Faculty of Pharmaceutical Medicine.

Robert is the Chief Medical Officer and a Managing Partner based in the UK and has over 30 years' global experience in drug development.

In his role as a consultant, Robert acts as Chief Medical Officer or Medical Director for a number of our clients. Dr Miller’s provision of medical expertise and strategic planning is at the core of his experience, as well as medical consultancy services and monitoring. He has represented companies as the medical expert in front of various regulatory authorities, providing the medical expertise for high level regulatory submission documents.

Robert trained at the London Hospital Medical College and practiced in general surgery, gynaecology and as a cardiothoracic surgeon before moving into pharmaceuticals in 1988. He worked for Zeneca and Protodigm before being a founding member and Chief Medical Officer of the consultancy firm Fulcrum Pharma Developments.

Robert is a Fellow of the Royal College of Surgeons, Royal Society of Medicine, and the Faculty of Pharmaceutical Medicine.

David is a Managing Partner based at the Strasbourg office and has over 25 years' global experience in clinical drug development.

David is an expert in clinical development strategy and oversight, with a specialty in Oncology. He has worked on projects with a variety tumour and compound types (cytotoxics, cytostatics, biologicals, radiopharmaceuticals, gene therapy etc).

During his career David worked for Hoffmann-La Roche before leading a group of Project Managers at Quintiles. He was a Senior Clinical Director at Fulcrum Pharma Developments and then Aptiv Solutions in the Early Phase Development Group. He has led numerous development programmes from Entry into Man through to successful NDAs in industry leading timeframes.

Peter is Head of Chemistry, Manufacturing and Controls (CMC) and has over 25 years’ experience in drug development.

He has particular experience and expertise in supporting Asian clients with manufacturing operations and regulatory submissions in Europe and the US.

He began his career at Chiroscience in Cambridge before moving to Roche. Peter then worked for emerging pharma companies where he gained experience in formulation development, drug product manufacturing and CMC Regulatory Affairs.

Peter has been providing bespoke CMC consultancy for more than 10 years, initially at Fulcrum Pharma Developments and now at Artemida Pharma.

Peter has a PhD in Organic Chemistry from the University of Manchester Institute of Science and Technology (UMIST) and is a Fellow of the Royal Society of Chemistry.

Helene is a Project Director based at the Strasbourg office with over 20 years’ experience in the pharmaceutical industry.

As an expert in clinical trial management, Helene leads cross-functional teams in the delivery of the clinical side of drug development programs.

Helene has been involved with projects focusing mainly on Oncology with a variety of compound types (cytotoxics, cytostatics, biologicals, cancer vaccines and radiopharmaceuticals) and in a wide range of indications.

During her early career Helene worked at Quintiles, managing mainly phase III studies. Moving to Fulcrum Pharma Developments, Aptiv Solutions and then Artemida Pharma, she expanded her experience in early phase drug development, managing multiple phase I and phase II oncology studies.

Jenny is a Regulatory Affairs Consultant based in the UK and has over 40 years’ experience across all areas of drug development.

Jenny is an expert in strategic regulatory consulting, having worked in many therapeutic areas with various novel products. With Artemida Pharma she brings her extensive US and European experience to deliver both strategic and hands-on support throughout drug development for pharma and biotech clients.

She has a thorough background in pharmaceutical regulatory affairs including roles with Merck, Sharp & Dohme and E.R. Squibb and leading the regulatory consulting services at AKOS and Fulcrum Pharma.

Jenny has a Pharmacy degree from the University of Manchester and is a Fellow of TOPRA, The Organisation for Regulatory Affairs.